Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18–30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial

Authors

Zhaojun Mo (ORCID: https://orcid.org/0000-0001-5183-4302)
Changgui Li (ORCID: https://orcid.org/0000-0002-9660-0216)
Lili Huang (ORCID: https://orcid.org/0000-0003-3084-4936)
Xiaowei Gao (ORCID: https://orcid.org/0000-0003-3273-7499)
Shi Liwei
Guohua Li (ORCID: https://orcid.org/0000-0002-9073-3907)
Juan Li (ORCID: https://orcid.org/0000-0001-8320-2406)
Qi Li (ORCID: https://orcid.org/0000-0002-5127-2896)
Yanxia Wang (ORCID: https://orcid.org/0000-0001-6045-4643)
Lin Yuan (ORCID: https://orcid.org/0000-0001-8013-4313)
Zhao Gao (ORCID: https://orcid.org/0000-0003-4541-9019)
Bang‐Wei Yu
H W Fan (ORCID: https://orcid.org/0000-0001-9216-0076)

Institutions

Walmart (United States) (US)
Xian Center for Disease Control and Prevention (CN)
Shanghai CASB Biotechnology (China) (CN)
National Institutes for Food and Drug Control (CN)
Guangxi Center for Disease Prevention and Control (CN)
Hebei Provincial Center for Disease Control and Prevention (CN)
Yunnan Yingmao Biotechnology (China) (CN)
Henan Provincial Center for Disease Control and Prevention (CN)

Publication Details

Journal: BMC Infectious Diseases
Published: 2025-12-18
DOI: https://doi.org/10.1186/s12879-025-12064-1
Primary Topic: Cervical Cancer and HPV Research
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18–30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial

Zhaojun Mo, Changgui Li, Lili Huang, Xiaowei Gao et al.

Dec 18, 2025

BMC Infectious Diseases

Cervical Cancer and HPV Research

article

Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18–30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial

Zhaojun Mo, Changgui Li, Lili Huang, Xiaowei Gao, Shi Liwei, Guohua Li, Juan Li, Qi Li, Yanxia Wang, Lin Yuan, Zhao Gao, Bang‐Wei Yu, H W Fan

December 18, 2025article en

Abstract

No abstract available for this paper.

BMC Infectious DiseasesVol. 26(1)

Walmart (United States) (US), Xian Center for Disease Control and Prevention (CN), Shanghai CASB Biotechnology (China) (CN), National Institutes for Food and Drug Control (CN), Guangxi Center for Disease Prevention and Control (CN), Hebei Provincial Center for Disease Control and Prevention (CN), Yunnan Yingmao Biotechnology (China) (CN), Henan Provincial Center for Disease Control and Prevention (CN)

Openalex Percentile: Top 47%

Cervical Cancer and HPV Research

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18–30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial — Zhaojun Mo, Changgui Li, et al. · BMC Infectious Diseases (2025) | TGRS Research Map | TGRS